Cardiovascular disease burden in the North Africa and Middle East region: an analysis of the global burden of disease study 1990-2021.

Autor: Soleimani H; Cardiovascular Diseases Research Institute, Tehran Heart Center, Tehran University of Medical Sciences, TUMS, Tehran, 1995614331, Iran., Nasrollahizadeh A; Cardiovascular Diseases Research Institute, Tehran Heart Center, Tehran University of Medical Sciences, TUMS, Tehran, 1995614331, Iran. ali.nasrollahi75@gmail.com.; Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. ali.nasrollahi75@gmail.com., Nasrollahizadeh A; Cardiovascular Diseases Research Institute, Tehran Heart Center, Tehran University of Medical Sciences, TUMS, Tehran, 1995614331, Iran., Razeghian I; School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran., Molaei MM; School of Medicine, Tehran University of Medical Sciences, Tehran, Iran., Hakim D; Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Nasir K; Department of Cardiovascular Medicine, Houston Methodist DeBakey Heart and Vascular Center, Houston, TX, USA., Al-Kindi S; Department of Cardiovascular Medicine, Houston Methodist DeBakey Heart and Vascular Center, Houston, TX, USA., Hosseini K; Cardiovascular Diseases Research Institute, Tehran Heart Center, Tehran University of Medical Sciences, TUMS, Tehran, 1995614331, Iran.
Jazyk: angličtina
Zdroj: BMC cardiovascular disorders [BMC Cardiovasc Disord] 2024 Dec 19; Vol. 24 (1), pp. 712. Date of Electronic Publication: 2024 Dec 19.
DOI: 10.1186/s12872-024-04390-0
Abstrakt: Aims: Cardiovascular diseases (CVD) are a leading cause of mortality and morbidity in the North Africa and Middle East (NAME) region. Due to the paucity of research on this issue, we aimed to estimate the burden of CVD and its attributable risk factors in the NAME region.
Methods and Results: Data from the Global Burden of Disease (GBD) were retrieved to estimate the incidence, prevalence, deaths, years of life lost, years lived with disability, disability-adjusted life years (DALYs) for CVD across 21 countries and both sexes. From 1990 to 2021, the incidence of CVD increased, but the age-standardized incidence rate slightly declined. The prevalence of CVD rose, with stable age-standardized prevalence rates. Additionally, the age-standardized DALY rate decreased from 11421.8 to 7353.8 per 100,000 people. Men consistently had higher rates of incidence, prevalence, deaths, and DALYs compared to women. Ischemic heart disease, stroke, and hypertensive heart disease were the leading causes of DALYs. Furthermore, high systolic blood pressure, dietary risks, and high LDL cholesterol were the top risk factors across NAME countries. countries with a history of war or ongoing conflict experience higher rates of death, disease burden (DALYs), and disease incidence compared to countries without such a history.
Conclusion: Despite the Progress in reducing the CVD burden in the NAME region, CVD remains a major public health problem, specifically due to significant sex disparities and various socio-economic factors. The study highlights the need for targeted interventions addressing these disparities and socio-economic determinants.
Clinical Trial Number: not applicable.
Competing Interests: Declarations. Competing interests: The authors declare no competing interests.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: